Kevin Feeley Sells 402 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 402 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the sale, the chief financial officer now directly owns 5,044 shares of the company’s stock, valued at $454,212.20. This trade represents a 7.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total value of $362,565.79.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.

GeneDx Trading Down 4.1 %

Shares of GeneDx stock opened at $94.46 on Tuesday. The stock has a fifty day moving average price of $84.69 and a 200-day moving average price of $70.37. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The firm has a market cap of $2.65 billion, a PE ratio of -48.19 and a beta of 1.91. GeneDx Holdings Corp. has a 1 year low of $7.72 and a 1 year high of $115.60.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. TD Cowen increased their price target on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their target price on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $72.33.

Institutional Investors Weigh In On GeneDx

Hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. purchased a new stake in GeneDx in the third quarter worth $604,000. GSA Capital Partners LLP purchased a new stake in GeneDx in the 3rd quarter worth about $322,000. Royce & Associates LP bought a new stake in GeneDx in the 3rd quarter valued at about $1,201,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in GeneDx during the third quarter valued at about $2,547,000. Finally, Charles Schwab Investment Management Inc. boosted its position in GeneDx by 304.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after purchasing an additional 110,666 shares during the period. Institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.